Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy(358 views) Catalano L, Pace L, Califano C, Pinto AM, De Renzo A, Di Gennaro F, Del Vecchio S, Fonti R, Salvatore M, Rotoli B
Haematologica (ISSN: 0390-6078, 0006-4971, 0006-6497), 1998 Nov 15; 92(10): 119-124.
Keywords: 99mtc-Mibi, Bone Scintigraphy, Multiple Myeloma, Osteolysis, Methoxy Isobutyl Isonitrile Technetium Tc 99m, Adult, Aged, Article, Female, Human, Intravenous Drug Administration, Major Clinical Study, Monoclonal Immunoglobulinemia, Plasmacytoma, Whole Body Scintiscanning, 80 And Over, Bone Marrow Neoplasms, Diagnostic Imaging, Middle Aged, Radionuclide Imaging, Radiopharmaceuticals, Technetium Tc 99m Sestamibi,
Affiliations: Ctro. C.N.R. per la Med. Nucleare, Napoli, Italy
Cattedra di Ematologia, Università Federico II, via Pansini 5, 80131 Naples, Italy
Ctro. C. N. R. per la Med. Nucleare, Napoli, Italy
Dipartimento di Medicina Clinica e Sperimentale, Facolta di Medicina e Chirurgia, Universita Federico II, Napoli, Italy.,
References: Scutellari, P.N., Spanedda, R., Feggi, L.M., Cervi, P.M., The value and limitations of total body scan in the diagnosis of multiple myeloma: A comparison with conventional skeletal radiography (1985) Haematologica, 70, pp. 136-14
Kao, C.H., Wang, S.J., Liu, T.J., The use of technetium-99m-methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses (1994) Eur J Nucl Med, 21, pp. 432-436
Hassan, I., Sahweil, A., Costantinides, C., Mahmoud, A., Nair, M., Abdel-Dayem, H., Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl-isonitrile in benign and malignant lesions in the lungs (1989) Clin Nucl Med, 14, pp. 333-340
Durie, B.G.M., Waxman, A., Jochelson, M., Giles, F.J., Hamburg, G., Avedon, M., Technetium-99m-MIBI scanning in multiple myeloma (MM) (1994) Proc Am Soc Clin Oncol, 13, p. 411
Malpas, J.S., Tirovola, E.B., Biassoni, L., Kaleva, N., Kouykin, V., Britton, K.E., Myeloma imaging with Tc-99m MIBI (1995) Proc. 5th International Workshop on Multiple Myeloma, p. 120. , La Baule, France, 10-13 September
Unlu, M., Haznedar, R., Atavci, S., Inanir, S., Targut, B., Detection of bone lesion in multiple myeloma using Tc-99m MIBI scintigraphy (1995) Eur J Nucl Med, 22 (SUPPL.), p. 739
Adams, B.K., Fataar, A., Nizami, M.A., Technetium-99m-sestaMIBI uptake in myeloma (1996) J Nucl Med, 37, pp. 1001-1002
Pace, L., Catalano, L., Pinto, A.M., Different patterns of technetium-99m-sestaMIBI scintigraphy in multiple myeloma (1998) Eur J Nucl Med, 25, pp. 714-720
Ciarmiello, A., Del Vecchio, S., Silvestro, P., Tumor clearance of 99mtc-sestaMIBI as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer (1998) J Clin Oncol, 16, pp. 1677-1683
Chiu, M.L., Kronauge, J.F., Piwnica-Worms, D., Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutyl isonitrile) technetium in cultured mouse fibroblasts (1990) J Nucl Med, 31, pp. 1646-1653
Scutellari, P. N., Spanedda, R., Feggi, L. M., Cervi, P. M., The value and limitations of total body scan in the diagnosis of multiple myeloma: A comparison with conventional skeletal radiography (1985) Haematologica, 70, pp. 136-14
Kao, C. H., Wang, S. J., Liu, T. J., The use of technetium-99m-methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses (1994) Eur J Nucl Med, 21, pp. 432-436
Durie, B. G. M., Waxman, A., Jochelson, M., Giles, F. J., Hamburg, G., Avedon, M., Technetium-99m-MIBI scanning in multiple myeloma (MM) (1994) Proc Am Soc Clin Oncol, 13, p. 411
Malpas, J. S., Tirovola, E. B., Biassoni, L., Kaleva, N., Kouykin, V., Britton, K. E., Myeloma imaging with Tc-99m MIBI (1995) Proc. 5th International Workshop on Multiple Myeloma, p. 120. , La Baule, France, 10-13 September
Adams, B. K., Fataar, A., Nizami, M. A., Technetium-99m-sestaMIBI uptake in myeloma (1996) J Nucl Med, 37, pp. 1001-1002
Chiu, M. L., Kronauge, J. F., Piwnica-Worms, D., Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutyl isonitrile) technetium in cultured mouse fibroblasts (1990) J Nucl Med, 31, pp. 1646-1653
Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy
Background and Objective. The tracer technetium-99m-2-methoxy-isobutyl-isonitrile (Tc99m-sestaMIBI) has recently been shown to concentrate in some neoplastic tissues, including myeloma. We investigated the diagnostic capacity and limits of this procedure in tracing focal myeloma lesions, and compared them with those of conventional radiological procedures (Xr). Design and Methods. We studied 55 patients suffering from multiple myeloma (MM) or solitary plasmacytoma in different stages and clinical conditions, or from monoclonal gammopathy of undefined significance (MGUS), by whole body scans obtained 10 minutes after injection of 555 MBq of Tc99m-sestaMIBI. Scans were defined as normal (physiological uptake only), diffuse (presence of bone marrow uptake), or focal(localized areas of uptake), and were compared to conventional skeletal Xr. Results. Thirty patients showed no focal areas of Tc99m-sestaMIBI uptake; this group consisted of 5 patients with MGUS, 6 with MM in stage IA and 2 in stage IIA, 11 patients studied after effective chemotherapy and 6 in early relapse. Twenty-five patients showed one or more spots of focal uptake: all of them had active disease (untreated, resistant or relapsing MM). In the setting of tracing focal lesions, Tc99m-sestaMIBI scans were concordant with the radiological examination in 38 patients and discordant in 17. Among the latter, in 4 cases Tc99m-sestaMIBI revealed focal lesions not detected by Xr, and in 13 cases lytic areas detected by Xr did not show Tc99m-sestaMIBI uptake. Interpretation and Conclusions. In untreated patients, the number of lesions revealed by Tc99m-sestaMIBI was comparable to that shown by Xr, while in pretreated patients Tc99m-sestaMIBI traced a number of lesions lower than that detected by Xr. The reason for this discrepancy is that Tc99m-sestaMIBI traces only active lesions. Tc99m-sestaMIBI limitations in identifying focal lesions may derive from the dimension of the smallest traceable lesion (about one centimeter), and from the possibility that focal plasma cell localizations in collapsed bone may not be visualized due to inadequate vascularization. Tc99m-sestaMIBI scintigraphy is an interesting tool for diagnosing, staging and following up focal myeloma lesions, in the bone as well as in soft tissues. It is more specific than conventional Xr in identifying sites of active disease. (C)1999, Ferrata Storti Foundation.
Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(694 views) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 ViewExport to BibTeXExport to EndNote